NeueHealth (NEUE) Financials
Newest figures come from the 10-Q for Q2 FY2025, filed Aug 7, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NEUE SEC filings page.
NeueHealth, Inc. (NEUE) reported $890.4M in revenue over the twelve months to Jun 30, 2025, down 13.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Operating losses narrowed sharply despite lower sales, but liabilities still exceed assets and short-term coverage remains constrained.
In FY2023, operating cash flow was-$2.73B against a net loss of$1.15B , so cash consumption substantially exceeded the accounting loss. In FY2024, those measures were-$123.2M and a net loss of$134.7M , making earnings and cash much more closely aligned.
Revenue fell
The balance sheet remains structurally stretched: liabilities were
Financial Health Signals
Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of NeueHealth, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
NeueHealth, Inc. has an operating margin of -11.5%, meaning the company loses $11 on every $100 of revenue. This results in a profitability score of 24/100. This is up from -49.7% the prior year.
NeueHealth, Inc.'s revenue declined 19.3% year-over-year, from $1.2B to $936.7M. This contraction results in a growth score of 69/100.
NeueHealth, Inc.'s current ratio of 0.61 is below the typical benchmark, resulting in a score of 7/100. This tight liquidity could limit financial flexibility if cash inflows slow.
NeueHealth, Inc.'s operations used $123.2M of cash, and capex of $2.3M added to the outflow, for a free cash flow shortfall of $125.5M. This results in a cash flow score of 4/100.
NeueHealth, Inc. scores -10.94, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $4.4B against total assets of $544.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
NeueHealth, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
NeueHealth, Inc. reported a net loss of $134.7M while operations used $123.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
NeueHealth, Inc. reported an operating loss of $107.4M against $18.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
NeueHealth, Inc. generated $209.1M in revenue in Q2 2025. This represents a decrease of 7.5% from the same quarter a year earlier. Against the prior quarter it is down 3.1%.
NeueHealth, Inc.'s EBITDA was $17.8M in Q2 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 186.4%.
NeueHealth, Inc. reported a net loss of $10.1M in Q2 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NeueHealth, Inc. earned -$2.62 per diluted share (EPS) in Q2 2025. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
NeueHealth, Inc. recorded an outflow of $4.5M in free cash flow in Q2 2025, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NeueHealth, Inc. held $131.6M in cash against $212.4M in long-term debt as of Q2 2025.
Not reported for Q2 2025.
Margins & Returns
NeueHealth, Inc.'s operating margin was 6.8% in Q2 2025, reflecting core business profitability. This is up 23.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.6 percentage points.
NeueHealth, Inc.'s net profit margin was -4.8% in Q2 2025, showing the share of revenue converted to profit. This is up 21.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
Not reported for Q2 2025.
Not reported for Q2 2025.
Capital Allocation
NeueHealth, Inc. invested $1.6M in capex in Q2 2025, funding long-term assets and infrastructure. This represents an increase of 100.1% from the same quarter a year earlier. Against the prior quarter it is up 58.6%.
Not reported for Q2 2025.
Not reported for Q2 2025.
NEUE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $209.1M-7.5% | $215.8M-12.0% | $232.6M-20.6% | $232.9M-13.5% | $226.0M-24.2% | $245.1M-18.5% | $292.9M-48.6% | $269.4M+39.3% |
| SG&A Expenses | N/A | N/A | N/A | $7.5M-89.7% | $10.4M-85.2% | $7.7M-94.5% | -$256.6M | $72.5M-15.2% |
| Operating Income | $14.3Mn/m | $2.7Mn/m | -$29.4Mn/m | -$17.3Mn/m | -$37.5Mn/m | -$23.1Mn/m | -$45.9M | -$462.8Mn/m |
| EBITDA | $17.8Mn/m | $6.2Mn/m | -$25.8Mn/m | -$13.8Mn/m | -$33.6Mn/m | -$18.5Mn/m | -$41.9M | -$458.7Mn/m |
| Interest Expense | $6.9M+67.3% | $6.6M+126.5% | $6.2M-44.2% | $5.4M-46.1% | $4.1M-55.2% | $2.9M-62.4% | $11.2M | $10.0M+104.7% |
| Income Tax | -$21Kn/m | $111K-83.3% | -$672K-142.3% | $2.8Mn/m | -$187Kn/m | $663K-47.3% | $1.6M | -$3.4M-199.5% |
| Net Income | -$10.1Mn/m | -$11.7Mn/m | -$2.7Mn/m | -$57.4Mn/m | -$58.6Mn/m | -$15.9Mn/m | -$229.7Mn/m | -$633.9Mn/m |
| EPS (Basic) | -$2.62 | -$2.90n/m | -$1.88 | -$8.51n/m | -$8.65n/m | -$3.53 | -$30.33 | -$81.03 |
| EPS (Diluted) | -$2.62 | -$2.90n/m | -$1.88 | -$8.51n/m | -$8.65n/m | -$3.53 | -$30.33 | -$81.03 |
| Diluted Shares (Avg) | 9M | 9M+6.1% | N/A | 8M+3.8% | 8M+3.7% | 8M | N/A | 8M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
NEUE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $743.7M-17.1% | $895.7M-19.0% | $544.4M-55.6% | $696.8M-66.1% | $897.3M-79.6% | $1.1B-77.2% | $1.2B-73.7% | $2.1B-55.4% |
| Current Assets | $639.9M-18.5% | $788.2M-19.1% | $434.6M-60.1% | $589.4M-69.2% | $785.6M-79.6% | $974.5M-74.2% | $1.1B-69.5% | $1.9B-27.5% |
| Cash & Equivalents | $131.6M-1.4% | $138.1M+22.5% | $83.3M-4.6% | $109.8M-3.2% | $133.4M+23.9% | $112.8M-70.5% | $87.3M-59.8% | $113.4M-92.9% |
| Short-Term Investments | $13.9M+59.7% | $7.0Mn/m | $9.9M+57.6% | $8.8M+5567.9% | $8.7M+5499.4% | $0-100.0% | $6.3M+620.9% | $156K-99.9% |
| Accounts Receivable | $53.1M+47.7% | $41.7M+4.5% | $36.6M-6.4% | $43.1M+31.9% | $35.9M+30.0% | $39.9M-68.1% | $39.1M+99.7% | $32.7M-72.9% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $344K-100.0% |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0-100.0% |
| Total Liabilities | $2.1B-4.1% | $2.3B-4.6% | $1.9B-23.7% | $2.0B-34.1% | $2.2B-54.4% | $2.4B-54.4% | $2.5B-48.8% | $3.1B-26.9% |
| Current Liabilities | $908.4M-13.0% | $1.1B-15.5% | $710.2M-49.0% | $872.4M-52.3% | $1.0B-71.3% | $1.3B-68.6% | $1.4B-62.3% | $1.8B-43.7% |
| Non-Current Liabilities | $1.2B+3.8% | $1.2B+7.8% | $1.2B+8.3% | $1.2B-8.1% | $1.2B-2.8% | $1.1B-5.9% | $1.1B-6.3% | $1.3B+27.5% |
| Long-Term Debt | $212.4M+80.5% | $207.4M+212.3% | $202.6M+205.1% | $120.3M | $117.7M | $66.4M | $66.4Mn/m | N/A |
| Total Equity | -$1.4Bn/m | -$1.4Bn/m | -$1.4Bn/m | -$1.4Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.1B-393.8% |
| Retained Earnings | -$4.5Bn/m | -$4.5Bn/m | -$4.4Bn/m | -$4.4Bn/m | -$4.4Bn/m | -$4.3Bn/m | -$4.3Bn/m | -$4.1Bn/m |
Not reported in any period shown, so not listed: Inventory.
NEUE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8Mn/m | -$21.0Mn/m | -$24.4Mn/m | -$21.7Mn/m | -$28.4Mn/m | -$48.7Mn/m | -$331.2M-370.0% | -$1.7Bn/m |
| Depreciation & Amortization | $3.6M-10.6% | $3.6M-22.0% | $3.6M-10.4% | $3.5M-15.0% | $4.0M-35.2% | $4.6M-53.9% | $4.0M-61.4% | $4.1M-70.3% |
| Stock-Based Compensation | N/A | $5.6M-70.1% | N/A | N/A | N/A | $18.6M-44.1% | N/A | N/A |
| Capital Expenditures | $1.6M+100.1% | $1.0M+1503.1% | $791K+191.9% | $665K+186.6% | $813K+53.1% | $64K-96.6% | $271K-95.4% | $232K-96.4% |
| Free Cash Flow | -$4.5Mn/m | -$22.1Mn/m | -$25.2Mn/m | -$22.3Mn/m | -$29.2Mn/m | -$48.8Mn/m | -$331.5M-383.8% | -$1.7Bn/m |
| Investing Cash Flow | -$8.5Mn/m | $63.2M-68.2% | -$2.3Mn/m | -$51K-100.0% | -$9.1Mn/m | $198.4M-71.1% | -$25.8M-177.2% | $988.3M+102.3% |
| Financing Cash Flow | -$547K-101.1% | -$2.7Mn/m | -$14.3M-260.4% | -$13.3M-129.0% | $49.6Mn/m | -$275.5Mn/m | $8.9M-94.8% | $46.0M-84.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NEUE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 6.8%+23.4pp | 1.2%+10.7pp | -12.6%+3.0pp | -7.4% | -16.6%-8.8pp | -9.4%+5.5pp | -15.7% | -171.8% |
| Net Margin | -4.8%+21.1pp | -5.4%+1.1pp | -1.2%+77.3pp | -24.6% | -25.9%+11.9pp | -6.5%+51.7pp | -78.4% | -235.3% |
| Return on Assets | -1.4%+5.2pp | -1.3%+0.1pp | -0.5%+18.2pp | -8.2%+22.6pp | -6.5%-4.0pp | -1.4%+2.2pp | -18.7%-4.2pp | -30.8%-24.0pp |
| Current Ratio | 0.700.0x | 0.740.0x | 0.61-0.2x | 0.68-0.4x | 0.75-0.3x | 0.77-0.2x | 0.78-0.2x | 1.04+0.2x |
| Asset Turnover | 0.280.0x | 0.240.0x | 0.43+0.2x | 0.33+0.2x | 0.25+0.2x | 0.22+0.2x | 0.24+0.1x | 0.13+0.1x |
| FCF Margin | -2.1%+10.8pp | -10.2%+9.7pp | -10.8% | -9.6% | -12.9%+23.8pp | -19.9% | -113.2% | -620.5% |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.4B), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.61), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NeueHealth, Inc. NEUE | FY2024 | $936.7M | -$134.7M | -14.4% | $60.9M | 27/100 |
| Progyny, Inc. PGNY | FY2025 | $1.3B | $58.5M | 4.5% | $2.2B | 69/100 |
| Clover Health Investments, Corp CLOV | FY2025 | $1.9B | -$85.5M | -4.5% | $2.4B | 41/100 |
| Alignment Healthcare, Inc. ALHC | FY2025 | $3.9B | -$724K | 0.0% | $1.6B | 55/100 |
| Oscar Health, Inc. OSCR | FY2025 | $11.7B | -$443.2M | -3.8% | $9.6B | 46/100 |
Where NeueHealth, Inc. Ranks
Frequently Asked Questions
What is NeueHealth, Inc.'s annual revenue?
NeueHealth, Inc. (NEUE) reported $936.7M in total revenue for fiscal year 2024. This represents a -19.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NeueHealth, Inc.'s revenue growing?
NeueHealth, Inc. (NEUE) revenue declined by 19.3% year-over-year, from $1.2B to $936.7M in fiscal year 2024.
Is NeueHealth, Inc. profitable?
No, NeueHealth, Inc. (NEUE) reported a net loss of $81.9M over the trailing 12 months to June 30, 2025. In fiscal year 2024 it reported a net loss of $134.7M, with a net profit margin of -14.4%.
What is NeueHealth, Inc.'s EBITDA?
NeueHealth, Inc. (NEUE) had EBITDA of -$91.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does NeueHealth, Inc. have?
As of fiscal year 2024, NeueHealth, Inc. (NEUE) had $83.3M in cash and equivalents against $202.6M in long-term debt.
What is NeueHealth, Inc.'s operating margin?
NeueHealth, Inc. (NEUE) had an operating margin of -11.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is NeueHealth, Inc.'s net profit margin?
NeueHealth, Inc. (NEUE) had a net profit margin of -14.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is NeueHealth, Inc.'s free cash flow?
NeueHealth, Inc. (NEUE) recorded an outflow of $125.5M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NeueHealth, Inc.'s operating cash flow?
NeueHealth, Inc. (NEUE) recorded an outflow of $123.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are NeueHealth, Inc.'s total assets?
NeueHealth, Inc. (NEUE) had $544.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are NeueHealth, Inc.'s capital expenditures?
NeueHealth, Inc. (NEUE) invested $2.3M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is NeueHealth, Inc.'s current ratio?
NeueHealth, Inc. (NEUE) had a current ratio of 0.61 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is NeueHealth, Inc.'s return on assets (ROA)?
NeueHealth, Inc. (NEUE) had a return on assets of -24.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does NeueHealth, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, NeueHealth, Inc. (NEUE) held $93.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $123.2M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is NeueHealth, Inc.'s debt-to-equity ratio negative or not reported?
NeueHealth, Inc. (NEUE) has negative shareholder equity of -$1.4B as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is NeueHealth, Inc.'s Altman Z-Score?
NeueHealth, Inc. (NEUE) has an Altman Z-Score of -10.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is NeueHealth, Inc.'s Piotroski F-Score?
NeueHealth, Inc. (NEUE) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NeueHealth, Inc.'s earnings high quality?
NeueHealth, Inc. (NEUE) reported a net loss of $134.7M while operations used $123.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can NeueHealth, Inc. cover its interest payments?
NeueHealth, Inc. (NEUE) reported an operating loss of $107.4M against $18.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is NeueHealth, Inc.?
NeueHealth, Inc. (NEUE) scores 27 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.